Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
暂无分享,去创建一个
P. Sorger | N. Gray | K. Westover | J. Mancias | Jinhua Wang | C. Mills | K. Subramanian | Miljan Kuljanin | F. Ferguson | Lianbo Li | W. Harshbarger | S. Gondi | Yan Liu | F. M. Ferguson | Caitlin E. Mills
[1] Charles Y. Lin,et al. Discovery of a selective inhibitor of Doublecortin Like Kinase 1 , 2020, Nature Chemical Biology.
[2] Jun Peng,et al. Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments , 2020, Cancers.
[3] A. Lin,et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.
[4] R. Vogel,et al. CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells , 2019, Pharmaceuticals.
[5] Samantha Dale Strasser,et al. Tissue-Specific Oncogenic Activity of KRASA146T. , 2019, Cancer discovery.
[6] K. Ueno,et al. Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer , 2018, AntiCancer Research.
[7] Y. Hata,et al. Doublecortin-like kinase 1 compromises DNA repair and induces chromosomal instability , 2018, Biochemistry and biophysics reports.
[8] S. Tavangar,et al. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[9] Min Liu,et al. DCLK1 promotes epithelial‐mesenchymal transition via the PI3K/Akt/NF‐κB pathway in colorectal cancer , 2018, International journal of cancer.
[10] Michael Peyton,et al. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer , 2018, Cell.
[11] Samantha Dale Strasser,et al. Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis , 2018, Science Signaling.
[12] E. Feldman,et al. Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization , 2018, bioRxiv.
[13] J. Murray,et al. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). , 2017, Journal of medicinal chemistry.
[14] S. Knapp,et al. Characterization of a highly selective inhibitor of the Aurora kinases. , 2017, Bioorganic & medicinal chemistry letters.
[15] T. Wang,et al. Functional implication of Dclk1 and Dclk1-expressing cells in cancer , 2017, Small GTPases.
[16] Gerald C. Chu,et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism , 2017, Nature Communications.
[17] S. Gygi,et al. Proteome-Wide Protein Expression Profiling Across Five Pancreatic Cell Lines , 2017, Pancreas.
[18] J. Yates,et al. DCLK1 phosphorylates the microtubule‐associated protein MAP7D1 to promote axon elongation in cortical neurons , 2017, Developmental neurobiology.
[19] Takafumi Yoshida,et al. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1 , 2017, Molecular Cancer Research.
[20] R. May,et al. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells , 2017, Molecular Cancer.
[21] Weiwen Dai,et al. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. , 2016, Structure.
[22] Jian Liu,et al. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer , 2016, Journal of Cancer Research and Clinical Oncology.
[23] H. Koga,et al. Pancreatic DCLK1 marks quiescent but oncogenic progenitors: a possible link to neuroendocrine tumors. , 2016, Stem cell investigation.
[24] R. May,et al. Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. , 2016, Cancer research.
[25] A. S. Nateri,et al. Spheroid-Formation (Colonosphere) Assay for in Vitro Assessment and Expansion of Stem Cells in Colon Cancer , 2016, Stem Cell Reviews and Reports.
[26] Miao Tang,et al. miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1. , 2016, Biochemical and biophysical research communications.
[27] S. Steinbacher,et al. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site , 2016, Acta crystallographica. Section D, Structural biology.
[28] P. Sorger,et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.
[29] B. Honig,et al. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. , 2016, Cell stem cell.
[30] P. Krawczyk,et al. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients , 2016, Clinical and Translational Oncology.
[31] Zhenfeng Duan,et al. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer , 2016, Oncotarget.
[32] R. May,et al. Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells , 2016, Journal of carcinogenesis & mutagenesis.
[33] C. Hoogenraad,et al. Microtubule‐binding protein doublecortin‐like kinase 1 (DCLK1) guides kinesin‐3‐mediated cargo transport to dendrites , 2016, The EMBO journal.
[34] S. Arii,et al. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis , 2016, PloS one.
[35] Fumiaki Sato,et al. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1 , 2016, Molecular Cancer Research.
[36] Jeremy D O'Connell,et al. Proteome-wide quantitative multiplexed profiling of protein expression: carbon-source dependency in Saccharomyces cerevisiae , 2015, Molecular biology of the cell.
[37] S. Lightfoot,et al. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism , 2015, Oncotarget.
[38] T. Wang,et al. Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal , 2015, Oncotarget.
[39] P. Jänne,et al. Development of small molecules targeting the pseudokinase Her3. , 2015, Bioorganic & medicinal chemistry letters.
[40] S. Islam,et al. Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells , 2015, Oncotarget.
[41] Zujiang Yu,et al. Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth , 2015, Scientific Reports.
[42] A. Wittinghofer,et al. Structural Characterization of LRRK2 Inhibitors. , 2015, Journal of medicinal chemistry.
[43] W. Tierney,et al. DCLK1 Is Detectable in Plasma of Patients with Barrett’s Esophagus and Esophageal Adenocarcinoma , 2015, Digestive Diseases and Sciences.
[44] R. May,et al. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma , 2014, Oncotarget.
[45] P. Jänne,et al. Pharmacological Targeting of the Pseudokinase Her3 , 2014, Nature chemical biology.
[46] S. Lightfoot,et al. Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition , 2014, Oncotarget.
[47] T. Wang,et al. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. , 2014, Cancer letters.
[48] P. Nordlund,et al. The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.
[49] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[50] Shibing Deng,et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.
[51] R. May,et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1 , 2014, Molecular Cancer.
[52] Lorne Zinman,et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis , 2014, Nature Neuroscience.
[53] Linheng Li,et al. Brief Report: Dclk1 Deletion in Tuft Cells Results in Impaired Epithelial Repair After Radiation Injury , 2014, Stem cells.
[54] Linheng Li,et al. Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury. , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[55] R. Lothe,et al. The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer , 2014, Epigenetics.
[56] R. Postier,et al. DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer , 2013, PloS one.
[57] J. Gleeson,et al. Doublecortin-like kinase enhances dendritic remodelling and negatively regulates synapse maturation , 2013, Nature Communications.
[58] R. Kageyama,et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine , 2012, Nature Genetics.
[59] Collin M. Stultz,et al. Molecular Basis for Specific Regulation of Neuronal Kinesin-3 Motors by Doublecortin Family Proteins , 2012, Molecular cell.
[60] Bob van de Water,et al. Combining Doublecortin-Like Kinase Silencing and Vinca Alkaloids Results in a Synergistic Apoptotic Effect in Neuroblastoma Cells , 2012, Journal of Pharmacology and Experimental Therapeutics.
[61] C. Bellows,et al. DCLK1 immunoreactivity in colorectal neoplasia , 2012, Clinical and experimental gastroenterology.
[62] P. Workman,et al. Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.
[63] E. Halperin,et al. Matrin 3 Binds and Stabilizes mRNA , 2011, PloS one.
[64] N. Gray,et al. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.
[65] U. McDermott,et al. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 , 2011, ACS medicinal chemistry letters.
[66] R. Versteeg,et al. Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. , 2010, Endocrine-related cancer.
[67] N. Osheroff,et al. DNA topoisomerase II, genotoxicity, and cancer. , 2007, Mutation research.
[68] Péter Lénárt,et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.
[69] J. Peters,et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.
[70] G. Eichele,et al. The evolving doublecortin (DCX) superfamily , 2006, BMC Genomics.
[71] James C. Wang,et al. Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[72] A. Mayeda,et al. CDK11 Complexes Promote Pre-mRNA Splicing* , 2003, The Journal of Biological Chemistry.
[73] C. Walsh,et al. DCAMKL1 Encodes a Protein Kinase with Homology to Doublecortin that Regulates Microtubule Polymerization , 2000, The Journal of Neuroscience.
[74] Wei Li,et al. DNA topoisomerase IIβ and neural development , 2000 .
[75] M. Mizuguchi,et al. High expression of doublecortin and KIAA0369 protein in fetal brain suggests their specific role in neuronal migration. , 1999, The American journal of pathology.
[76] K. Sossey-Alaoui,et al. DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar to doublecortin (DCX). , 1999, Genomics.
[77] C. Austin,et al. Eukaryotic DNA topoisomerase IIβ , 1998 .
[78] F M Richards,et al. Areas, volumes, packing and protein structure. , 1977, Annual review of biophysics and bioengineering.
[79] G. Heiduschka,et al. Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies , 2016, European Archives of Oto-Rhino-Laryngology.
[80] A. Maitra,et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. , 2014, Gastroenterology.
[81] C Sander,et al. Polarity as a criterion in protein design. , 1989, Protein engineering.